Hexarelin vs Eloralintide
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone Peptides
HexarelinGLP-1 / Weight Loss Agonists
Eloralintide- Summary
- Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
- Eloralintide is a long-acting amylin analog under development by OPKO Health. Amylin is co-secreted with insulin and regulates post-meal glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Eloralintide is designed for once-weekly dosing, differentiating it from the short-acting pramlintide (Symlin). It is being studied for obesity and type 2 diabetes as a complement to GLP-1 based therapies.
- Half-Life
- ~70 minutes
- ~7 days (estimated, long-acting design)
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 100–200 mcg
- Under investigation in Phase 1/2 trials
- Frequency
- 2–3 times daily
- Once weekly
- Key Benefits
- Strongest GH pulse per mcg among GHRPs
- Unique direct cardioprotective effects via CD36
- Increased IGF-1 and muscle anabolism
- Accelerated recovery from training
- Bone density support
- Anti-aging via GH axis
- Potential cardiac rehabilitation benefits
- Once-weekly dosing (vs multiple daily injections for pramlintide)
- Appetite suppression via central amylin receptor activation
- Reduction in post-meal glucagon secretion
- Complementary mechanism to GLP-1 agonists for combination therapy
- Slows gastric emptying for prolonged satiety
- Potential additive weight loss when combined with GLP-1 agents
- Side Effects
- Water retention
- Elevated cortisol
- Elevated prolactin (more pronounced than other GHRPs)
- Receptor desensitization with continuous use
- +1 more
- Nausea
- Vomiting
- Decreased appetite
- Injection site reactions
- +1 more
- Stacks With
- —
- —